Galecto (GLTO) Competitors $2.57 +0.08 (+3.21%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$2.50 -0.07 (-2.92%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLTO vs. ME, NRSN, CLDI, SLGL, MEIP, COCP, SYBX, IPA, QNTM, and MTVAShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include 23andMe (ME), NeuroSense Therapeutics (NRSN), Calidi Biotherapeutics (CLDI), Sol-Gel Technologies (SLGL), MEI Pharma (MEIP), Cocrystal Pharma (COCP), Synlogic (SYBX), ImmunoPrecise Antibodies (IPA), Quantum Biopharma (QNTM), and MetaVia (MTVA). These companies are all part of the "pharmaceutical products" industry. Galecto vs. 23andMe NeuroSense Therapeutics Calidi Biotherapeutics Sol-Gel Technologies MEI Pharma Cocrystal Pharma Synlogic ImmunoPrecise Antibodies Quantum Biopharma MetaVia 23andMe (NASDAQ:ME) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation. Is ME or GLTO more profitable? Galecto has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. Galecto's return on equity of -76.96% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets 23andMe-183.39% -170.07% -62.13% Galecto N/A -76.96%-66.59% Does the media refer more to ME or GLTO? In the previous week, 23andMe had 5 more articles in the media than Galecto. MarketBeat recorded 8 mentions for 23andMe and 3 mentions for Galecto. Galecto's average media sentiment score of 0.30 beat 23andMe's score of 0.05 indicating that Galecto is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 23andMe 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Galecto 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor ME or GLTO? Galecto received 20 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 60.38% of users gave Galecto an outperform vote while only 46.15% of users gave 23andMe an outperform vote. CompanyUnderperformOutperform23andMeOutperform Votes1246.15% Underperform Votes1453.85% GalectoOutperform Votes3260.38% Underperform Votes2139.62% Do analysts rate ME or GLTO? Galecto has a consensus price target of $10.00, suggesting a potential upside of 289.11%. Given Galecto's stronger consensus rating and higher probable upside, analysts clearly believe Galecto is more favorable than 23andMe.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 23andMe 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ME or GLTO? 23andMe has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Galecto has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Which has preferable valuation and earnings, ME or GLTO? Galecto has lower revenue, but higher earnings than 23andMe. Galecto is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio23andMe$208.78M0.06-$666.70M-$15.45-0.03GalectoN/AN/A-$38.35M-$18.61-0.14 Do insiders & institutionals have more ownership in ME or GLTO? 36.1% of 23andMe shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 26.3% of 23andMe shares are held by insiders. Comparatively, 11.9% of Galecto shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryGalecto beats 23andMe on 10 of the 17 factors compared between the two stocks. Remove Ads Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.40M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.136.7921.7217.82Price / SalesN/A225.96376.8894.61Price / CashN/A65.6738.1534.64Price / Book0.095.866.474.00Net Income-$38.35M$141.86M$3.20B$247.23M7 Day Performance5.33%4.50%2.86%1.45%1 Month Performance-36.54%-12.65%-8.55%-6.24%1 Year Performance-84.85%-11.06%10.58%0.60% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto2.4299 of 5 stars$2.57+3.2%$10.00+289.1%-85.0%$3.40MN/A-0.1340Short Interest ↑ME23andMe1.454 of 5 stars$0.50-35.3%$9.40+1,787.6%-93.8%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeNRSNNeuroSense Therapeutics0.4699 of 5 stars$0.97-2.0%N/A-30.7%$13.26MN/A-1.5210Short Interest ↑Gap UpCLDICalidi Biotherapeutics1.7233 of 5 stars$0.50flat$15.00+2,923.6%N/A$13.13M$50,000.000.0038SLGLSol-Gel Technologies2.8389 of 5 stars$0.47+0.9%$5.00+963.8%-41.9%$13.09M$11.71M-1.3850Positive NewsMEIPMEI Pharma2.5136 of 5 stars$1.93-3.5%$7.00+262.7%-37.2%$12.86M$65.30M-0.34100Short Interest ↓Gap DownCOCPCocrystal Pharma2.7447 of 5 stars$1.26-11.3%$7.00+455.6%-4.2%$12.82MN/A-0.6810Positive NewsGap DownSYBXSynlogic2.0911 of 5 stars$1.08flatN/A-41.9%$12.63M$8,000.00-0.2680Positive NewsGap DownIPAImmunoPrecise Antibodies2.6982 of 5 stars$0.40+12.3%$4.00+889.6%-66.9%$12.56M$24.00M-0.5280Short Interest ↓QNTMQuantum BiopharmaN/A$6.36-10.0%N/AN/A$12.21MN/A-0.41N/AGap DownMTVAMetaVia2.2476 of 5 stars$1.40-4.0%$12.00+756.5%N/A$12.13MN/A0.0010News CoverageGap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies 23andMe Competitors NeuroSense Therapeutics Competitors Calidi Biotherapeutics Competitors Sol-Gel Technologies Competitors MEI Pharma Competitors Cocrystal Pharma Competitors Synlogic Competitors ImmunoPrecise Antibodies Competitors Quantum Biopharma Competitors MetaVia Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLTO) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLTO Stock Free GLTO Stock Alerts